Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ANAB

AnaptysBio (ANAB)

AnaptysBio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ANAB
DateTimeSourceHeadlineSymbolCompany
11/27/20234:17PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANABAnaptysBio Inc
11/27/20234:15PMGlobeNewswire Inc.Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa PharmaceuticalsNASDAQ:ANABAnaptysBio Inc
11/07/20234:15PMGlobeNewswire Inc.Anaptys Named a BioSpace 2024 Best Places to Work WinnerNASDAQ:ANABAnaptysBio Inc
11/02/20234:21PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANABAnaptysBio Inc
11/02/20234:18PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANABAnaptysBio Inc
11/02/20234:15PMGlobeNewswire Inc.Anaptys Announces Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:ANABAnaptysBio Inc
11/01/20239:15AMGlobeNewswire Inc.Anaptys Announces Participation in November Investor ConferencesNASDAQ:ANABAnaptysBio Inc
10/25/20234:43PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANABAnaptysBio Inc
10/11/20239:15AMGlobeNewswire Inc.Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV CongressNASDAQ:ANABAnaptysBio Inc
10/10/20239:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANABAnaptysBio Inc
10/09/20238:43AMDow Jones NewsAnaptys Sees Positive Trial Results for Imsidolimad Psoriasis TreatmentNASDAQ:ANABAnaptysBio Inc
10/09/20238:15AMGlobeNewswire Inc.Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25NASDAQ:ANABAnaptysBio Inc
10/09/20238:00AMGlobeNewswire Inc.Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)NASDAQ:ANABAnaptysBio Inc
10/02/20234:32PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ANABAnaptysBio Inc
09/18/20236:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANABAnaptysBio Inc
09/18/20236:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANABAnaptysBio Inc
09/18/20236:09PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ANABAnaptysBio Inc
09/18/20234:18PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANABAnaptysBio Inc
09/18/20234:15PMGlobeNewswire Inc.AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of DirectorsNASDAQ:ANABAnaptysBio Inc
09/12/20239:15AMGlobeNewswire Inc.AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual SummitNASDAQ:ANABAnaptysBio Inc
08/07/20234:21PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANABAnaptysBio Inc
08/07/20234:18PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANABAnaptysBio Inc
08/07/20234:15PMGlobeNewswire Inc.AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:ANABAnaptysBio Inc
07/31/20232:27PMDow Jones NewsAnaptysBio Shares Rise 11% After Jemperli Plus Chemotherapy Approved in U.S.NASDAQ:ANABAnaptysBio Inc
07/31/20231:34PMGlobeNewswire Inc.AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial CancerNASDAQ:ANABAnaptysBio Inc
05/30/20234:15PMGlobeNewswire Inc.AnaptysBio Announces Participation in Upcoming Investor ConferencesNASDAQ:ANABAnaptysBio Inc
05/11/20234:21PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ANABAnaptysBio Inc
05/11/20234:18PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ANABAnaptysBio Inc
05/11/20234:15PMGlobeNewswire Inc.AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline UpdateNASDAQ:ANABAnaptysBio Inc
05/02/20239:15AMGlobeNewswire Inc.AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)NASDAQ:ANABAnaptysBio Inc
 Showing the most relevant articles for your search:NASDAQ:ANAB

Your Recent History

Delayed Upgrade Clock